Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand EczemaGlobeNewsWire • 04/21/20
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque PsoriasisGlobeNewsWire • 03/16/20
Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate CommunicationsGlobeNewsWire • 03/05/20
Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewsWire • 03/03/20
Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque PsoriasisGlobeNewsWire • 02/13/20